Receptor activator of nuclear factor-κB ligand is a novel inducer of myocardial inflammation

Cardiovascular Research

Volumn 94, Issue 1, 2012, Pages 105-114

  Ock, Sangmi ^a   Ahn, Jihyun ^a   Lee, Seok Hong ^a   Park, Hongryeol ^b   Son, Jang Won ^a   Oh, Jae Gyun ^c   Yang, Dong Kwon ^c   Lee, Wang Soo ^a   Kim, Ho Shik ^d   Rho, Jaerang ^e   Oh, Goo Taeg ^f   Abel, Evan Dale ^g   Park, Woo Jin ^c   Min, Jeong Ki ^h,i   Kim, Jaetaek ^a  

^a Chung Ang University   (South Korea)

^b Yonsei University   (South Korea)

^c Gwangju Institute of Science and Technology (GIST)   (South Korea)

^d The Catholic University of Korea   (South Korea)

^e Chungnam National University   (South Korea)

^f Ewha Womans University   (South Korea)

^g UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^h Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

ⁱ University of Science and Technology (UST)   (South Korea)

Author keywords

Cardiomyocytes; NF B; Proinflammatory cytokine; RANKL

Indexed keywords

I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; LOSARTAN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; MONOCLONAL ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHOLIPASE C; PHOSPHOLIPASE C INHIBITOR; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; AUTOCRINE EFFECT; CONTROLLED STUDY; CYTOKINE PRODUCTION; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; MALE; MOUSE; MYOCARDITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; UPREGULATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; AUTOCRINE COMMUNICATION; CARDIOMEGALY; CELLS, CULTURED; CYTOKINES; DISEASE MODELS, ANIMAL; INFLAMMATION MEDIATORS; INTERLEUKIN-1ALPHA; INTERLEUKIN-1BETA; LOSARTAN; MALE; MICE; MICE, INBRED C57BL; MYOCARDITIS; MYOCYTES, CARDIAC; RANK LIGAND; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RNA INTERFERENCE; RNA, MESSENGER; SIGNAL TRANSDUCTION; TIME FACTORS; TNF RECEPTOR-ASSOCIATED FACTOR 2; TNF RECEPTOR-ASSOCIATED FACTOR 6; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 84859038834     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvs078     Document Type: Article

References (39)

1. Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K et al. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007;115:e69-e171.
2. Li M, Georgakopoulos D, Lu G, Hester L, Kass DA, Hasday J et al. p38 MAP kinase mediates inflammatory cytokine induction in cardiomyocytes and extracellular matrix remodeling in heart. Circulation 2005;111:2494-2502.
3. Abe J. Role of PKCs and NF-kappaB activation in myocardial inflammation: enemy or ally? J Mol Cell Cardiol 2007;43:404-408.
4. Feldman AM, Combes A, Wagner D, Kadakomi T, Kubota T, Li YY et al. The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol 2000; 35:537-544.
5. Mann DL. Stress-activated cytokines and the heart: from adaptation to maladaptation. Annu Rev Physiol 2003;65:81-101.
6. Torre-Amione G. Immune activation in chronic heart failure. Am J Cardiol 2005;95: 3C-8C.
7. Bozkurt B, Kribbs SB, Clubb FJ Jr, Michael LH, Didenko VV, Hornsby PJ et al. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation 1998;97: 1382-1391.
8. Kubota T, McTiernan CF, Frye CS, Demetris AJ, Feldman AM. Cardiac-specific overexpression of tumor necrosis factor-alpha causes lethal myocarditis in transgenic mice. J Card Fail 1997;3:117-124.
9. Dunlay SM, Weston SA, Redfield MM, Killian JM, Roger VL. Tumor necrosis factoralpha and mortality in heart failure: a community study. Circulation 2008;118:625-631.
10. Bujak M, Frangogiannis NG. The role of IL-1 in the pathogenesis of heart disease. Arch Immunol Ther Exp 2009;57:165-176.
11. Kong YY, Boyle WJ, Penninger JM. Osteoprotegerin ligand: a regulator of immune responses and bone physiology. Immunol Today 2000;21:495-502.
12. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93:165-176.
13. Kim YM, Kim YM, Lee YM, Kim HS, Kim JD, Choi Y et al. TNF-related activation-induced cytokine (TRANCE) induces angiogenesis through the activation of Src and phospholipase C (PLC) in human endothelial cells. J Biol Chem 2002; 277:6799-6805.
14. Min JK, Kim YM, Kim SW, Kwon MC, Kong YY, Hwang IK et al. TNF-related activation-induced cytokine enhances leukocyte adhesiveness: induction of ICAM-1 and VCAM-1 via TNF receptor-associated factor and protein kinase C-dependent NF-kappaB activation in endothelial cells. J Immunol 2005;175:531-540.
15. Min JK, Cho YL, Choi JH, Kim Y, Kim JH, Yu YS et al. Receptor activator of nuclear factor (NF)-kappaB ligand (RANKL) increases vascular permeability: impaired permeability and angiogenesis in eNOS-deficient mice. Blood 2007;109:1495-1502.
16. Kim J, Min JK, Park JA, Doh HJ, Choi YS, Rho J et al. Receptor activator of nuclear factor kappaB ligand is a novel inducer of tissue factor in macrophages. Circ Res 2010;107:871-876.
17. Panizo S, Cardus A, Encinas M, Parisi E, Valcheva P, López-Ongil S et al. RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway. Circ Res 2009;104:1041-1048.
18. Wallis DE, Penckofer S, Sizemore GW. The 'sunshine deficit' and cardiovascular disease. Circulation 2008;118:1476-1485.
19. Ueland T, Yndestad A, Oøie E, Florholmen G, Halvorsen B, Froøland SS et al. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation 2005;111:2461-2468.
20. Helske S, Kovanen PT, Lindstedt KA, Salmela K, Lommi J, Turto H et al. Increased circulating concentrations and augmented myocardial extraction of osteoprotegerin in heart failure due to left ventricular pressure overload. Eur J Heart Fail 2007;9: 357-363.
21. Yoon PO, Lee MA, Cha H, Jeong MH, Kim J, Jang SP et al. The opposing effects of CCN2 and CCN5 on the development of cardiac hypertrophy and fibrosis. J Mol Cell Cardiol 2010;49:294-303.
22. Cha H, Kim JM, Oh JG, Jeong MH, Park CS, Park J et al. PICOT is a critical regulator of cardiac hypertrophy and cardiomyocyte contractility. J Mol Cell Cardiol 2008;45: 796-803.
23. O'Neill BT, Kim J, Wende AR, Theobald HA, Tuinei J, Buchanan J et al. A conserved role for phosphatidylinositol 3-kinase but not Akt signaling in mitochondrial adaptations that accompany physiological cardiac hypertrophy. Cell Metab 2007;6:294-306.
24. Wong BR, Rho J, Arron J, Robinson E, Orlinick J, Chao M et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 1997;272:25190-25194.
25. Baker KM, Aceto JF. Angiotensin II stimulation of protein synthesis and cell growth in chick heart cells. Am J Physiol 1990;259:H610-H618.
26. Rockman HA, Wachhorst SP, Mao L, Ross J Jr. ANG II receptor blockade prevents ventricular hypertrophy and ANF gene expression with pressure overload in mice. Am J Physiol 1994;266:H2468-H2475.
27. Furuya Y, Mori K, Ninomiya T, Tomimori Y, Tanaka S, Takahashi N et al. Increased bone mass in mice after single injection of anti-receptor activator of nuclear factorkappaB ligand-neutralizing antibody: evidence for bone anabolic effect of parathyroid hormone in mice with few osteoclasts. J Biol Chem 2011;286:37023-37031.
28. Roodman GD, Windle JJ. Paget disease of bone. J Clin Invest 2005;115:200-208.
29. Traenckner EB, Pahl HL, Henkel T, Schmidt KN, Wilk S, Baeuerle PA. Phosphorylation of human I kappa B-alpha on serines 32 and 36 controls I kappa B-alpha proteolysis and NF-kappa B activation in response to diverse stimuli. EMBO J 1995;14: 2876-2883.
30. Sundaram K, Nishimura R, Senn J, Youssef RF, London SD, Reddy SV. RANK ligand signaling modulates the matrix metalloproteinase-9 gene expression during osteoclast differentiation. Exp Cell Res 2007;313:168-178.
31. Chung JY, Park YC, Ye H, Wu H. All TRAFs are not created equal: common and distinct molecular mechanisms of TRAF-mediated signal transduction. J Cell Sci 2002;115: 679-688.
32. LiuW,Wang S,Wei S, Sun L, Feng X. Receptor activator of NF-kappaB (RANK) cytoplasmic motif, 369PFQEP373, plays a predominant role in osteoclast survival in part by activating Akt/PKB and its downstream effector AFX/FOXO4. J Biol Chem 2005; 280:43064-43072.
33. Lockyer P, Schisler JC, Patterson C, Willis MS. Minireview:Won't get fooled again: the nonmetabolic roles of peroxisome proliferator-activated receptors (PPARs) in the heart. Mol Endocrinol 2010;24:1111-1119.
34. Karsdal MA, Hjorth P, Henriksen K, Kirkegaard T, Nielsen KL, Lou H et al. Transforming growth factor-beta controls human osteoclastogenesis through the p38 MAPK and regulation of RANK expression. J Biol Chem 2003;278: 44975-44987.
35. Chen Y, Wang X, Di L, Fu G, Chen Y, Bai L et al. Phospholipase Cgamma2 mediates RANKL-stimulated lymph node organogenesis and osteoclastogenesis. J Biol Chem 2008;283:29593-29601.
36. Matsuo K, Owens JM, Tonko M, Elliott C, Chambers TJ,Wagner EF. Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation. Nat Genet 2000;24:184-187.
37. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002;3:889-901.
38. Wei S, Teitelbaum SL, Wang MW, Ross FP. Receptor activator of nuclear factorkappa b ligand activates nuclear factor-kappa b in osteoclast precursors. Endocrinology 2001;142:1290-1295.
39. Kim HH, Shin HS, Kwak HJ, Ahn KY, Kim JH, Lee HJ et al. RANKL regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. FASEB J 2002;17:2163-2165.